Andres McAllister
Chief Tech/Sci/R&D Officer bij BIOINVENT INTERNATIONAL AB
Vermogen: 4 784 $ op 31-03-2024
Profiel
Andres McAllister is currently the Chief Medical Officer at BioInvent International AB since 2017.
Prior to this, he worked as the Chief Scientific Officer at Debiopharm International SA from 2004 to 2015.
He also held positions as Director-Research & Development at Immune Design Corp., Non-Executive Director at Immunexpress Pty Ltd., and Principal at Institut Pasteur, The University of California, San Francisco, and Centre d'Immunologie Pierre Fabre.
Dr. McAllister holds a doctorate degree from Université Paris 1 Panthéon-Sorbonne and Universidad del Rosario.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 31-12-2022 | 3 009 ( 0.00% ) | 4 784 $ | 31-03-2024 |
Actieve functies van Andres McAllister
| Bedrijven | Functie | Begin |
|---|---|---|
| BIOINVENT INTERNATIONAL AB | Chief Tech/Sci/R&D Officer | 01-01-2017 |
Eerdere bekende functies van Andres McAllister
| Bedrijven | Functie | Einde |
|---|---|---|
Debiopharm International SA
 Debiopharm International SA Pharmaceuticals: MajorHealth Technology Debiopharm International SA operates as a biopharmaceutical development company with focus on biologics and drug evaluation, licensing and development. It formulates and develops products for the treatment of cancer, endometriosis, uterine fibroids and hepatitis. The company was founded in 1979 and is headquartered in Lausanne, Switzerland. | Chief Tech/Sci/R&D Officer | 01-09-2015 |
Immunexpress Pty Ltd.
 Immunexpress Pty Ltd. Medical SpecialtiesHealth Technology Immunexpress Pty Ltd. engages in creating molecular diagnostics for sepsis. The company was founded by Roslyn Brandon, Mervyn Rees Thomas and Richard Bruce Brandon and in 2006 and is headquartered in Toowong, Australia. | Director/Board Member | - |
| Centre d'Immunologie Pierre Fabre | Corporate Officer/Principal | - |
Institut Pasteur
 Institut Pasteur Investment Trusts/Mutual FundsMiscellaneous The Institut Pasteur is a private non-profit foundation which contributes to the prevention and treatment of disease, through research, education, and public health activities. The firm was founded in 1887, and is based in Paris. | Corporate Officer/Principal | - |
| The University of California, San Francisco | Corporate Officer/Principal | - |
Opleiding van Andres McAllister
| Université Paris 1 Panthéon-Sorbonne | Doctorate Degree |
| Universidad del Rosario | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| BIOINVENT INTERNATIONAL AB | Health Technology |
| Bedrijven in privébezit | 5 |
|---|---|
Institut Pasteur
Institut Pasteur Investment Trusts/Mutual FundsMiscellaneous The Institut Pasteur is a private non-profit foundation which contributes to the prevention and treatment of disease, through research, education, and public health activities. The firm was founded in 1887, and is based in Paris. | Miscellaneous |
Debiopharm International SA
Debiopharm International SA Pharmaceuticals: MajorHealth Technology Debiopharm International SA operates as a biopharmaceutical development company with focus on biologics and drug evaluation, licensing and development. It formulates and develops products for the treatment of cancer, endometriosis, uterine fibroids and hepatitis. The company was founded in 1979 and is headquartered in Lausanne, Switzerland. | Health Technology |
Immune Design Corp.
 Immune Design Corp. Pharmaceuticals: MajorHealth Technology Immune Design Corp. is a clinical-stage immunotherapy company focused on cancer with in vivo approaches designed to enable the body's immune system to fight disease. It develops multiple product candidates from its discovery platforms, ZVex and GLAAS. The company was founded by Steven G. Reed and David Baltimore on February 20, 2008 and is headquartered in Kenilworth, NJ. | Health Technology |
Immunexpress Pty Ltd.
Immunexpress Pty Ltd. Medical SpecialtiesHealth Technology Immunexpress Pty Ltd. engages in creating molecular diagnostics for sepsis. The company was founded by Roslyn Brandon, Mervyn Rees Thomas and Richard Bruce Brandon and in 2006 and is headquartered in Toowong, Australia. | Health Technology |
| Centre d'Immunologie Pierre Fabre |
